Background
Tran Health Pty Ltd and Bradfield Pharmacy Group Pty Ltd were equal partners in Bundall Chempro Chemist, a profitable pharmacy operated under a Chempro franchise. Tran Health’s director, Thanh Tran, was the managing partner. The proceeding began with Tran Health seeking urgent injunctive relief concerning an application for a pharmacy business licence under Queensland’s new licensing regime. Those claims were resolved after the requested relief narrowed and undertakings were accepted.
Bradfield Pharmacy then pursued a cross-application under s 38(f) of the Partnership Act 1891 (Qld) to dissolve the partnership and appoint receivers. The parties had clashed over the licence application, transactions with a compounding business operated by Ms Tran’s husband, unpaid rent from Ms Tran’s florist business, irregular cash banking, medicinal-cannabis dispensing arrangements, and their inability to arrange a partners’ meeting. They also produced materially different unsigned versions of the partnership agreement.
The Court’s Holding
Freeburn J held that it was just and equitable to dissolve the partnership because its working relationship had completely broken down. The resort to litigation over the licence application, Ms Tran’s continued dealings with her husband’s company after Bradfield raised concerns, the florist’s unpaid rent, legitimate concerns about banking practices, and the parties’ mutual hostility showed that the cooperation, trust, and confidence necessary between partners no longer existed. The Court did not find that Bradfield had raised a serious concern about the medicinal-cannabis arrangement in July 2023, but that did not alter the overall conclusion.
The parties’ inability to agree even on the terms of their partnership agreement provided an additional reason for dissolution because no agreed contractual mechanism existed for resolving their deadlock or permitting an orderly exit. The Court rejected Tran Health’s contention that dissolution and receivership would destroy the pharmacy: the partners retained authority to pursue the required pharmacy licence while winding up the partnership, and receivers could coordinate that process and preserve the business as a going concern.
The Court made orders for dissolution under s 38(f) and for the appointment of receivers and managers with powers to preserve, operate, and sell the partnership business. Critically, orders 2–13—including the dissolution and receivership—were expressly not to take effect until the orders made following a further hearing on 26 October 2026 concerning their form and costs were formally taken out.
Key Takeaways
- A complete breakdown of mutual cooperation, trust, and confidence can justify dissolving a partnership on the just-and-equitable ground even where the underlying business remains profitable.
- Conflicted related-party dealings, unpaid obligations to the partnership, poor financial practices, and litigation conduct may collectively establish that partners can no longer work together.
- Here, the ordered dissolution and receivership had deferred operation: they would not take effect until the orders made after the 26 October 2026 hearing were formally taken out.
Why It Matters
The decision emphasizes that profitability does not preserve a partnership whose essential relationship of confidence has collapsed. Courts will assess the parties’ dealings and litigation conduct as a whole rather than treating each dispute in isolation.
It also shows that a receivership can be structured to preserve a regulated business through licensing and sale. Practitioners must nevertheless distinguish between relief announced in reasons and relief already in force, particularly where the court expressly postpones the operative effect of its orders.